Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?
- PMID: 27000961
- DOI: 10.1038/nrclinonc.2016.47
Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?
Comment on
-
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1. Blood. 2016. PMID: 26932802 Clinical Trial.
References
-
- Blood. 2016 May 26;127(21):2561-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical